1572510-42-9

Basic information

• Product Name: JNJ-632
• Synonyms: JNJ-632
• CAS NO: 1572510-42-9
• Molecular Formula: C₁₈H₁₉FN₂O₄S
• Molecular Weight: 378.42
• EINECS: -0
• Product Categories: API
• Mol File: 1572510-42-9.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• Density: 1.39±0.1 g/cm3(Predicted)
• PKA: 10.37±0.20(Predicted)
• CAS DataBase Reference: JNJ-632(CAS DataBase Reference)
• NIST Chemistry Reference: JNJ-632(1572510-42-9)
• EPA Substance Registry System: JNJ-632(1572510-42-9)

Safety Data

• Hazardous Substances Data: 1572510-42-9(Hazardous Substances Data)

Usage

General Description

JNJ-632 is a potent and selective inhibitor of the protein tyrosine phosphatase 1B (PTP1B) enzyme, which plays a role in regulating insulin signaling and metabolism. By inhibiting PTP1B, JNJ-632 has potential therapeutic applications in treating type 2 diabetes and related metabolic disorders. Preclinical studies have demonstrated that JNJ-632 can improve insulin sensitivity and glucose tolerance, as well as reduce body weight and improve lipid metabolism in animal models of obesity and diabetes. Its mechanism of action and promising preclinical data make JNJ-632 a potential candidate for further development as a novel therapy for metabolic diseases.

Upstream product

• 4052-92-0 3-chlorosulfonylbenzoyl dichloride 
• 452-69-7 3-methyl-4-fluoroaniline 
• 104530-79-2 (S)-tetrahydrofuran-3-yl-amine 
• 104530-80-5 (S)-(-)-tetrahydro-3-furylamine p-toluenesulfonate salt 
• 1572515-74-2 3-(4-fluoro-3-methylphenylcarbamoyl)benzene-1-sulfonyl chloride 

Relevant articles and documents

Synthesis and Evaluation of N-Phenyl-3-sulfamoyl-benzamide Derivatives as Capsid Assembly Modulators Inhibiting Hepatitis B Virus (HBV)

Small molecule induced hepatitis B virus (HBV) capsid assembly modulation is considered an attractive approach for new antiviral therapies against HBV. Here we describe efforts toward the discovery of a HBV capsid assembly modulator in a hit-to-lead optimization, resulting in JNJ-632, a tool compound used to further profile the mode of action. Administration of JNJ-632 (54) in HBV genotype D infected chimeric mice resulted in a 2.77 log reduction of the HBV DNA viral load.

SULFAMOYL-ARYLAMIDES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B

Inhibitors of HBV replication of Formula (I) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein B, R1, R2 and R4 have the meaning as defined herein. The present invention also relates to pharmaceutical compositions containing these inhibitors and to their use, alone or in combination with other HBV inhibitors, in HBV therapy.